Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 8OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 82Gastrointestinal 20Gynecologic 12Breast 12Genitourinary 10Dermatologic 10Other solid neoplasm 8Endocrine 8CNS 7Other hematologic neoplasm 6Sarcoma 5Lymphoid 5Head & Neck 5Other 2Plasma cell 1Other neoplasm 1NET 1

Conditions

Neuroendocrine Tumors 20Carcinoma, Neuroendocrine 6von Hippel-Lindau Disease 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Melanoma 2Breast Neoplasms 2Vipoma 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

cabozantinib 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Small Cell Lung Carcinoma × NET × Clear all
NCT04079712 2026-04-13

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 12 charts
EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡